Literature DB >> 19206095

Adaptive designs for confirmatory clinical trials.

Frank Bretz1, Franz Koenig, Werner Brannath, Ekkehard Glimm, Martin Posch.   

Abstract

Adaptive designs play an increasingly important role in clinical drug development. Such designs use accumulating data of an ongoing trial to decide how to modify design aspects without undermining the validity and integrity of the trial. Adaptive designs thus allow for a number of possible adaptations at midterm: Early stopping either for futility or success, sample size reassessment, change of population, etc. A particularly appealing application is the use of adaptive designs in combined phase II/III studies with treatment selection at interim. The expectation has arisen that carefully planned and conducted studies based on adaptive designs increase the efficiency of the drug development process by making better use of the observed data, thus leading to a higher information value per patient.In this paper we focus on adaptive designs for confirmatory clinical trials. We review the adaptive design methodology for a single null hypothesis and how to perform adaptive designs with multiple hypotheses using closed test procedures. We report the results of an extensive simulation study to evaluate the operational characteristics of the various methods. A case study and related numerical examples are used to illustrate the key results. In addition we provide a detailed discussion of current methods to calculate point estimates and confidence intervals for relevant parameters.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19206095     DOI: 10.1002/sim.3538

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  72 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  An example of optimal phase II design for exposure response modelling.

Authors:  Alan Maloney; Marloes Schaddelee; Jan Freijer; Walter Krauwinkel; Marcel van Gelderen; Philippe Jacqmin; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-25       Impact factor: 2.745

3.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

4.  Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.

Authors:  Jan Regnstrom; Franz Koenig; Bo Aronsson; Tatiana Reimer; Kristian Svendsen; Stelios Tsigkos; Bruno Flamion; Hans-Georg Eichler; Spiros Vamvakas
Journal:  Eur J Clin Pharmacol       Date:  2009-11-20       Impact factor: 2.953

Review 5.  Efficiency perspectives on adaptive designs in stroke clinical trials.

Authors:  Ken Cheung; Petra Kaufmann
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

Review 6.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

Review 7.  Design and Endpoints of Clinical Trials, Current and Future.

Authors:  Morris Sherman
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

8.  Asymptotic properties of maximum likelihood estimators with sample size recalculation.

Authors:  Sergey Tarima; Nancy Flournoy
Journal:  Stat Pap (Berl)       Date:  2019-02-28       Impact factor: 2.234

9.  Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.

Authors:  Christopher S Coffey; Bruce Levin; Christina Clark; Cate Timmerman; Janet Wittes; Peter Gilbert; Sara Harris
Journal:  Clin Trials       Date:  2012-12       Impact factor: 2.486

Review 10.  HIV Prevention Interventions for Adolescents.

Authors:  Sybil Hosek; Audrey Pettifor
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.